Aspirin, flu and general practice research.
A few weeks ago I received an invitation on a stiff white card to a morning tea function at Government House in Melbourne. Being unaccustomed to the world of posh functions and stiff white invitations, and never having been inside Government House, I decided to go along. The occasion was the launch of the ASPirin in Reducing Events in the Elderly (ASPREE) trial into general practice. The cucumber sandwiches, served in dainty triangles (naturally with crusts removed) were indeed a treat. However, the importance of a large clinical trial undertaken in general practice and designed to answer a really important question that may result in a change in clinical practice, was really the star of the show.
Parsons
Jenni
J
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D001315:Australia; D035843:Biomedical Research / Q000592:standards / Q000639:trends; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005194:Family Practice / Q000592:standards / Q000639:trends; D005544:Forecasting; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
D001241:Aspirin